&w=3840&q=100)
KPIT stock slips 6% after mid-quarter update; should you buy, hold or sell?
KPIT Technologies share price today
Shares of KPIT Technologies slipped 6 per cent to ₹1,310.45 on the BSE in Tuesday's intra-day trade after the company in its mid-quarter update said that the overall business environment continues to be uncertain with rising geopolitical concerns and ambiguity around the overall tariff scenario.
In the past four trading days, the stock price of the computer software & consulting company has dipped 8 per cent. It had hit a 52-week low of ₹1,020.60 on April 7, 2025.
At 11:23 AM; KPIT was trading 5 per cent lower at ₹1,318.75 on the BSE. In comparison, the BSE Sensex was trading higher by 1.2 per cent at 82,848. The average trading volumes at the counter jumped nearly two-fold, with a combined 3.2 million shares changing hands on the NSE and BSE.
KPIT mid-quarter update
KPIT in its mid-quarter update said the 100 per cent acquisition of Caresoft's Global Engineering Solutions business, approved by the board on May 6, 2025, was expected to close by the end of the current quarter. Revenue from the acquired business is expected to be consolidated from Q2FY26, contributing an estimated 4 per cent growth in FY26 over FY25.
Additionally, the company expects increased offshoring to help optimise costs but has guided for the absence of one-time gains in Q1FY26 and a potential dip in other income due to forex volatility. Early but strategic wins have emerged in the Trucks and Off-highway segment, though some are partially cannibalising existing revenues due to clients' limited budgets. The deal pipeline remains strong, however, conversions and ramp-ups are slower than anticipated, especially in the US and Asia, while Europe shows relatively stronger momentum.
'For KPIT, the pipeline continues to be strong, though the conversions are much slower than expected. Substantial pipeline however is moving in a positive direction. In geographic, Europe is looking positive. USA /Asia are a bit uncertain. The ramp-ups for the wins are progressing at an even slower pace than what was anticipated at the end of the last quarter,' the company said. Track LIVE Stock Market Updates
ICICI Securities view on KPIT post mid-quarter update
KPIT's acquisition of Caresoft's Global Engineering Solutions business is a strategically aligned move that enhances its presence in the Trucks and Off-highway segment while strengthening its manufacturing engineering capabilities and supporting its entry into the China market. While the consolidation is expected to contribute around 4 per cent growth in FY26, the overall outlook remains tempered by macro uncertainties, including geopolitical risks and tariff-related ambiguity, ICICI Securities said in a note.
According to the brokerage view, the slower pace of deal conversions and ramp-ups (in the US and Asia), alongside some revenue cannibalisation from budget-constrained clients, could weigh on near-term performance. That said, continued offshoring and steady traction in Europe may offer some cushion, it added.
JM Financial Institutional Securities view on KPIT
KPIT did not provide any guidance for growth or margin for FY26. It cited difficulty in determining the pace of deal to revenue conversion as reason for the same. Though it did mention that some of these deals are already in the transition phase, suggesting imminent pick-up once clarity emerges.
Management indicated that while the macro environment remains fluid, the medium-term growth drivers are intact. They expect broad-based growth across geographies, with Europe anticipated a rebound as trade dynamics stabilize over the next few months. KPIT emphasized that transformation and large program ramps are expected to meaningfully contribute from H2 FY26. Margin stability remains a priority, with focus on AI-led productivity improvements, cost-effective delivery models, and platform-based engagement approaches.
Analysts at JM Financial Institutional Securities post Q4 results, lowered FY26 cc growth estimate by 300bps. However a 500bps favourable cross-currency swing (based on current FX) results in higher USD estimates, limiting changes to EPS. KPIT's order backlog and execution should help it navigate the current macro, the brokerage firm said in the result update.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
2 hours ago
- Mint
Anant Ambani to get THIS amount as salary as Executive Director of Reliance — Check details
Mukesh Ambani-run oil marketing major Reliance Industries appointed Anant Ambani as one of the company's Full-Time directors. As a board member, Anant Ambani will be paid ₹ 10 crore to ₹ 20 crore, according to an exchange filing on Sunday, 29 June 2025. The filing data shows that Ambani's annual salary will comprise the main salary component, along with perquisites and allowances. The company also highlighted that the annual increments will be determined by the HRNR Committee at Reliance. 'Salary, Perquisites and Allowances shall be in the range of ₹ 10 crore to ₹ 20 crore per annum. Annual increments shall be as determined by the HRNR Committee,' said Reliance in its BSE filing. The perquisites and allowances will include accommodation cost or house rent allowance, gas, electricity, water, among other provisions as per the Income Tax Act of 1961. Reliance's contribution to Anant Ambani's provident fund, superannuation or annuity fund, gratuity payable and encashment of leave will be carried out as per the rules of the firm. However, these extra benefits will be provided in addition to Anant Ambani's salary of ₹ 10-20 crore. On top of the take-home salary, Anant Ambani will also receive an extra payment based on the net profits of the company. The company will also grant reimbursements on expenses incurred by Anant Ambani, his wife and attendant's travelling, boarding and lodging, according to the company's disclosure. According to the official filing data, the board of directors held their meeting on 15 April 2025, and approved the appointment of Anant Ambani a the Whole-time Director, designated as an Executive Director for the next five years effective 1 May 2025. His salary component also comes along with security and medical reimbursement as per Reliance's policy for senior managerial executives. Anant Ambani has been appointed as the Whole-Time director at Reliance along with his Executive Director position for the next five years, effective 1 May 2025. 'The Board of Directors of the Company, at its meeting held on 25 April 2025, subject to the approval of members, appointed Shri Anant M. Ambani (DIN: 07945702) as a Whole-time Director, designated as an Executive Director, for a period of 5 (five) years, with effect from 1 May 2025,' said the company in the exchange filing.

Mint
2 hours ago
- Mint
Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at ₹25,689 crore valuation — Details here
Gujarat-based pharmaceutical giant Torrent Pharma announced on Sunday, 29 June 2025, that it is in definitive agreements with global investment giant KKR to acquire a majority stake in JB Chemicals, according to an exchange filing. The potential acquisition details show that the company plans to acquire J. B. Chemicals and Pharmaceuticals (JB Pharma) at an equity valuation of ₹ 25,689 crore on a fully diluted basis, which will be followed by a merger of the two companies. JB Pharma's promoter company, Tau Investment Holdings, is a KKR-owned investment vehicle which the global giant uses to own a stake in the pharma major. Tau Investment is a legally distinct legal entity of KKR & Co. Inc. Tau Investment currently holds a 47.84% stake in J. B. Chemicals and Pharmaceuticals, according to BSE data as on Sunday, 29 June 2025. The deal is set to be carried out in several phases. In the first phase, Torrent Pharma will acquire a 46.39% stake through a share purchase agreement (SPA), which will total ₹ 11,917 crore at the rate of ₹ 1,600 per share. After the first phase, the company will introduce a mandatory open offer to acquire up to 26% of JB Pharma shares from public stakeholders at an open offer price of ₹ 1,639.18 per share. The acquiring company also plans to acquire another 2.80% stake in the company from certain employees holding a stake of JB Pharma at the same price per share as KKR selling its stake. The company also announced its plans for a merger between Torrent and JB Pharma through a scheme of arrangement where every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharmaceuticals. 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability,' said Samir Mehta, the Executive Chairman of Torrent Pharma in the official statement. JB Chemicals & Pharmaceuticals shares closed 2.72% higher at ₹ 1,799.35 after Friday's stock market session, compared to ₹ 1,751.75 in the previous market close. Shares of the pharma company have given more than 398% returns on investment in the last five years. However, the stock has lost 0.03% in the last one-year period. On a year-to-date (YTD) basis, the shares are down 4.58% in 2025, but are currently trading 6.02% higher in the last one-month period. Torrent Pharmaceuticals shares also closed with 3.68% gains on Friday's market at ₹ 3,344.40, compared to ₹ 3,225.70 in the previous stock market session last week. Pharma major Torrent Pharmaceuticals shares have gained 181% in the last five years and are trading 21.35% higher in the last one-year period. The shares are trading 6.94% higher in the last five trading sessions. Read all stories by Anubhav Mukherjee

Mint
3 hours ago
- Mint
Torrent Pharma to acquire majority stake in KKR-backed JB Chemicals at ₹25,689 crore valuation — Details here
Gujarat-based pharmaceutical giant Torrent Pharma announced on Sunday, 29 June 2025, that it is in definitive agreements with global investment giant KKR to acquire a majority stake in JB Chemicals, according to an exchange filing. The potential acquisition details show that the company plans to acquire J. B. Chemicals and Pharmaceuticals (JB Pharma) at an equity valuation of ₹ 25,689 crore on a fully diluted basis, which will be followed by a merger of the two companies. JB Pharma's promoter company, Tau Investment Holdings, is a KKR-owned investment vehicle which the global giant uses to own a stake in the pharma major. Tau Investment is a legally distinct legal entity of KKR & Co. Inc. Tau Investment currently holds a 47.84% stake in J. B. Chemicals and Pharmaceuticals, according to BSE data as on Sunday, 29 June 2025. The deal is set to be carried out in several phases. In the first phase, Torrent Pharma will acquire a 46.39% stake through a share purchase agreement (SPA), which will total ₹ 11,917 crore at the rate of ₹ 1,600 per share. After the first phase, the company will introduce a mandatory open offer to acquire up to 26% of JB Pharma shares from public stakeholders at an open offer price of ₹ 1,639.18 per share. The acquiring company also plans to acquire another 2.80% stake in the company from certain employees holding a stake of JB Pharma at the same price per share as KKR selling its stake. The company also announced its plans for a merger between Torrent and JB Pharma through a scheme of arrangement where every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharmaceuticals. 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability,' said Samir Mehta, the Executive Chairman of Torrent Pharma in the official statement. JB Chemicals & Pharmaceuticals shares closed 2.72% higher at ₹ 1,799.35 after Friday's stock market session, compared to ₹ 1,751.75 in the previous market close. Shares of the pharma company have given more than 398% returns on investment in the last five years. However, the stock has lost 0.03% in the last one-year period. On a year-to-date (YTD) basis, the shares are down 4.58% in 2025, but are currently trading 6.02% higher in the last one-month period. Torrent Pharmaceuticals shares also closed with 3.68% gains on Friday's market at ₹ 3,344.40, compared to ₹ 3,225.70 in the previous stock market session last week. Pharma major Torrent Pharmaceuticals shares have gained 181% in the last five years and are trading 21.35% higher in the last one-year period. The shares are trading 6.94% higher in the last five trading sessions. Read all stories by Anubhav Mukherjee Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.